2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The influence of neoadjuvant radiochemotherapy (RCT) on programmed death-ligand 1 (PD-L1) expression, a predictive marker for programmed cell death protein 1 (PD-1) inhibitor therapy, was studied on tumour and inflammatory cells in rectal adenocarcinoma patients along with its prognostic value.

          Related collections

          Author and article information

          Journal
          Eur. J. Cancer
          European journal of cancer (Oxford, England : 1990)
          Elsevier BV
          1879-0852
          0959-8049
          Sep 2016
          : 65
          Affiliations
          [1 ] Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
          [2 ] Department of Nephropathology, Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
          [3 ] Department of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
          [4 ] Department of Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
          [5 ] Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany. Electronic address: luitpold.distel@uk-erlangen.de.
          Article
          S0959-8049(16)32279-1
          10.1016/j.ejca.2016.06.015
          27468145
          fbc81fc6-954d-4d08-b9be-83b4b990b851
          History

          Radiation,Radiochemotherapy,Radiotherapy,Rectal,Adenocarcinoma,Cancer,Nivolumab,PD-1,PD-L1,Pembrolizumab

          Comments

          Comment on this article